Chongqing Lummy Pharmaceutical Co., Ltd.

XSEC:300006 Stock Report

Market Cap: CN¥3.9b

Chongqing Lummy Pharmaceutical Past Earnings Performance

Past criteria checks 0/6

Chongqing Lummy Pharmaceutical has been growing earnings at an average annual rate of 38.4%, while the Pharmaceuticals industry saw earnings growing at 8.9% annually. Revenues have been declining at an average rate of 19.1% per year.

Key information

38.4%

Earnings growth rate

43.1%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-19.1%
Return on equity-4.3%
Net Margin-11.0%
Last Earnings Update31 Dec 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Chongqing Lummy Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:300006 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 24796-8853665
30 Sep 248561955090
30 Jun 248234653892
31 Mar 24850-1056094
31 Dec 23896-9595100
30 Sep 23858-8657580
30 Jun 23932-7467075
31 Mar 23913-4665772
01 Jan 23885-6965481
30 Sep 221,004-158769103
30 Jun 221,020-182742113
31 Mar 221,064-176773116
31 Dec 211,225-101853100
30 Sep 211,404-307970135
30 Jun 211,597-2861,058118
31 Mar 211,695-2701,099109
31 Dec 201,584-3271,039107
30 Sep 201,632-2311,035166
30 Jun 201,662-2171,059165
31 Mar 201,795-1841,135165
31 Dec 191,859-1551,113164
30 Sep 191,801741,00842
30 Jun 191,6697189144
31 Mar 191,5487375943
31 Dec 181,5629875443
30 Sep 181,4779573031
30 Jun 181,4409364245
31 Mar 181,3637957136
31 Dec 171,2825649231
30 Sep 171,1692137723
30 Jun 171,074183420
31 Mar 17990103110
31 Dec 1699073090
30 Sep 16966532850
30 Jun 16970422710
31 Mar 16974342670
31 Dec 15964212610
30 Sep 15999402300
30 Jun 15999452280
31 Mar 15992362300
31 Dec 1491292280
30 Sep 1482012230
30 Jun 14756-12090
31 Mar 14743192050

Quality Earnings: 300006 is currently unprofitable.

Growing Profit Margin: 300006 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 300006 is unprofitable, but has reduced losses over the past 5 years at a rate of 38.4% per year.

Accelerating Growth: Unable to compare 300006's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 300006 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.4%).

Return on Equity

High ROE: 300006 has a negative Return on Equity (-4.25%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/23 17:11
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Chongqing Lummy Pharmaceutical Co., Ltd. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullChangjiang Securities Co. LTD.
Chao LiCitic Securities Co., Ltd.
Wen Liang CuiFounder Securities Co., Ltd.